Test e-Mail 1
This is a test e-mail for Zapier. Making an edit. Making a second edit. Making a third edit. Making a 4th edit. Making 5th ... Read more
-
-
Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis
Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and ... Read more -
Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests
Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, ... Read more -
EMA Accepts Humira and Remicade Biosimilars for Regulatory Review
The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade ... Read more -
DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds
Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), or Cimzia (certolizumab), are less ... Read more
Test e-Mail 1
News
This is a test e-mail for Zapier. Making an edit. Making a second edit. Making a third edit. Making a 4th edit. Making 5th edit. ... Read more
Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis
News, rheumatoid arthritis
Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and Drug Administration approving the therapy in ... Read more
Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests
News, rheumatoid arthritis
Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according to results of a ... Read more
EMA Accepts Humira and Remicade Biosimilars for Regulatory Review
News
The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), used in the treatment ... Read more
DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds
News, rheumatoid arthritis
Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), or Cimzia (certolizumab), are less cost-effective compared to DMARD combination ... Read more
Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs
News, rheumatoid arthritis
Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid arthritis (RA) who have not ... Read more
Learning Sessions Help Rheumatologists Take Better Care of RA Patients, Study Says
News
Group-based quality improvement sessions, based on the recommended “treat to target” (TTT) approach, can help rheumatologists improve the quality of their care for rheumatoid arthritis (RA) patients, a recent ... Read more
Potential Treatment Sirukumab Up Before FDA and EMA with High Expectations, J&J Reports
News, rheumatoid arthritis
A potential treatment for moderate-to-severe rheumatoid arthritis, sirukumab, is under consideration by the U.S. Food and Drug Administration for approval, with the application supported by results from five Phase 3 clinical ... Read more
Can-Fite Files Clinical Trial Application in Canada for Piclidenoson to Treat RA
News
Can-Fite BioPharma has filed a clinical trial application (CTA) with Health Canada for piclidenoson (CF101) as a treatment for rheumatoid arthritis (RA). Piclidenoson is an orally bioavailable drug with a favorable ... Read more
Biosimilar CT-P13 Can Safely Replace Much More Expensive Remicade as RA Treatment, Study Finds
News
Rheumatoid arthritis (RA) patients taking Remicade (infliximab) can safely switch to CT-P13 (developed by Celltrion) — a much cheaper biosimilar of Remicade — according to a Norwegian study published in The Lancet. ... Read more